Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine and PfSPZ-CVac in Healthy Indonesian Adults
NCT03503058Phase 2Completed
- Sponsor
- Sanaria Inc.
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (4 arms), sponsored by Sanaria Inc. Primary endpoints: Number of Adverse Events Occurring After Investigational Product (IP) Administration at 20 months and Number of Participants With First Clinical Pf Malaria Cases at 42 weeks. Started May 2022; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03503058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503058.